

Akums gets approval to manufacture drug to treat *Helicobacter pylori*

The combikit includes, vonoprazan, which provides sustained suppression of gastric acid secretion, while the two antibiotics — clarithromycin + amoxicillin — deliver complementary antibacterial action.



New Delhi: Contract development and manufacturing organisation (CDMO) Akums Drugs and Pharmaceutical announced to have secured DCGI approval to manufacture a

combikit of clarithromycin + vonoprazan + amoxicillin for the treatment of *Helicobacter pylori* infection in adults.

The treatment pack combines, vonoprazan, a potassium-competitive acid blocker (P-CAB), which provides sustained suppression of gastric acid secretion, while the two antibiotics provide complementary antibacterial action. The prescribed regimen involves twice-daily dosing over a period of 14 days.

“While scientific development and therapeutic effectiveness remain central, the practical experience of patients undergoing treatment is also an important consideration. Our work in formulation development is guided by the need to address evolving healthcare requirements,” said Sanjeev Jain, MD, Akums Drugs and Pharmaceuticals.

News Source:

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/akums-gets-approval-to-manufacture-drug-to-treat-helicobacter-pylori/134400274>